ResearcherThe University of Texas at AustinNo recent work listed

Zeeshan Ramzan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 9 November 2026

Matched on ORCID iD 0000-0003-2643-4627; OpenAlex author ID A5038844495. Sources: OpenAlex.

Their work

Papers: 3 (first author 1, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 4

Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper

Papers 3

Current controversies and advances in the management of pancreatic adenocarcinoma. First author DOI 10.4251/wjgo.v13.i6.472 ↗
Lymphocyte-to-monocyte ratio can predict mortality in pancreatic adenocarcinoma. Last author DOI 10.4292/wjgpt.v8.i1.60 ↗
Survival analysis of veteran patients with pancreatic cancer. Last author DOI 10.1111/1751-2980.12361 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Muhammad Shehroz Zeeshan · 1 shared paper, 2021 · strength 0.28
- Paper Current controversies and advances in the management of pancreatic adenocarcinoma. DOI 10.4251/wjgo.v13.i6.472 ↗
David Kim · 2 shared papers, 2016–2017 · strength 0.15
- Paper Lymphocyte-to-monocyte ratio can predict mortality in pancreatic adenocarcinoma. DOI 10.4292/wjgpt.v8.i1.60 ↗
- Paper Survival analysis of veteran patients with pancreatic cancer. DOI 10.1111/1751-2980.12361 ↗
Gurshawn Singh · 1 shared paper, 2017 · strength 0.09
- Paper Lymphocyte-to-monocyte ratio can predict mortality in pancreatic adenocarcinoma. DOI 10.4292/wjgpt.v8.i1.60 ↗
Patricio Marcelo Polanco · 1 shared paper, 2016 · strength 0.06
- Paper Survival analysis of veteran patients with pancreatic cancer. DOI 10.1111/1751-2980.12361 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.